Compare Recursion Pharmaceuticals Inc (RXRX) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Super Micro Computer Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.78B), while Super Micro Computer Inc trades at $38.82 (market cap $24.33B). The key difference: Super Micro Computer Inc is far larger — about 13.7× Recursion Pharmaceuticals Inc's market cap, and Super Micro Computer Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SMCI | |
|---|---|---|
Market Cap | $1.78B | $24.33B |
Sector | Health | Technology |
52-Week High | $6.79 | $58.68 |
52-Week Low | $2.84 | $20.53 |
Enterprise Value | $1.30B | $31.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.
The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.
Super Micro Computer (SMCI) stock trades at $37.55, up 19.4% on strong Q4 2026 earnings that beat estimates with EPS of $1.70 versus $0.923 expected. The company reported 93% revenue growth year-over-year and issued aggressive fiscal 2027 revenue guidance of $65–72 billion. Technical indicators show a bullish trend with moving averages supporting upside, while RSI levels suggest potential overbought conditions near-term.
The outlook remains positive driven by robust AI infrastructure demand, but risks include execution challenges in meeting high growth targets and competitive pressures. Analyst consensus is a Buy with a $40.40 price target, indicating 7.6% upside from current levels, though margin compression and supply chain delays pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
